Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.

Daniele ManninaNico GagelmannAnita BadbaranMarkus DitschkowskiRashit BogdanovMarie RobinBruno CassinatMichael HeuserRabia ShahswarFelicitas TholDietrich BeelenNicolaus Kröger

Published in: European journal of haematology (2019)

These retrospective data suggest that MPL-mutated myelofibrosis patients have a favorable outcome after allogeneic transplantation with very low rate of disease relapse (5.5%) in comparison with the available historical controls regarding myelofibrosis in all.

Keyphrases

stem cell transplantation
high dose
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
bone marrow
low dose
peritoneal dialysis
prognostic factors
cross sectional
machine learning
stem cells
mesenchymal stem cells
deep learning
free survival